BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1477 related articles for article (PubMed ID: 33001135)

  • 1. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
    Yau T; Kang YK; Kim TY; El-Khoueiry AB; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox JJ; Ruth He A; El-Rayes BF; Acosta-Rivera M; Lim HY; Neely J; Shen Y; Wisniewski T; Anderson J; Hsu C
    JAMA Oncol; 2020 Nov; 6(11):e204564. PubMed ID: 33001135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
    Melero I; Yau T; Kang YK; Kim TY; Santoro A; Sangro B; Kudo M; Hou MM; Matilla A; Tovoli F; Knox J; He AR; El-Rayes B; Acosta-Rivera M; Lim HY; Soleymani S; Yao J; Neely J; Tschaika M; Hsu C; El-Khoueiry AB
    Ann Oncol; 2024 Jun; 35(6):537-548. PubMed ID: 38844309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
    Yau T; Zagonel V; Santoro A; Acosta-Rivera M; Choo SP; Matilla A; He AR; Cubillo Gracian A; El-Khoueiry AB; Sangro B; Eldawy TE; Bruix J; Frassineti GL; Vaccaro GM; Tschaika M; Scheffold C; Koopmans P; Neely J; Piscaglia F
    J Clin Oncol; 2023 Mar; 41(9):1747-1757. PubMed ID: 36512738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
    Oaknin A; Moore K; Meyer T; López-Picazo González J; Devriese LA; Amin A; Lao CD; Boni V; Sharfman WH; Park JC; Tahara M; Topalian SL; Magallanes M; Molina Alavez A; Khan TA; Copigneaux C; Lee M; Garnett-Benson C; Wang X; Naumann RW
    Lancet Oncol; 2024 May; 25(5):588-602. PubMed ID: 38608691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
    Saung MT; Pelosof L; Casak S; Donoghue M; Lemery S; Yuan M; Rodriguez L; Schotland P; Chuk M; Davis G; Goldberg KB; Theoret MR; Pazdur R; Fashoyin-Aje L
    Oncologist; 2021 Sep; 26(9):797-806. PubMed ID: 33973307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
    Hellmann MD; Rizvi NA; Goldman JW; Gettinger SN; Borghaei H; Brahmer JR; Ready NE; Gerber DE; Chow LQ; Juergens RA; Shepherd FA; Laurie SA; Geese WJ; Agrawal S; Young TC; Li X; Antonia SJ
    Lancet Oncol; 2017 Jan; 18(1):31-41. PubMed ID: 27932067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
    Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
    Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040).
    Sangro B; Yau T; El-Khoueiry AB; Kudo M; Shen Y; Tschaika M; Roy A; Feng Y; Gao L; Aras U
    Clin Transl Sci; 2023 Aug; 16(8):1445-1457. PubMed ID: 37165980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
    Yau T; Park JW; Finn RS; Cheng AL; Mathurin P; Edeline J; Kudo M; Harding JJ; Merle P; Rosmorduc O; Wyrwicz L; Schott E; Choo SP; Kelley RK; Sieghart W; Assenat E; Zaucha R; Furuse J; Abou-Alfa GK; El-Khoueiry AB; Melero I; Begic D; Chen G; Neely J; Wisniewski T; Tschaika M; Sangro B
    Lancet Oncol; 2022 Jan; 23(1):77-90. PubMed ID: 34914889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
    Antonia SJ; López-Martin JA; Bendell J; Ott PA; Taylor M; Eder JP; Jäger D; Pietanza MC; Le DT; de Braud F; Morse MA; Ascierto PA; Horn L; Amin A; Pillai RN; Evans J; Chau I; Bono P; Atmaca A; Sharma P; Harbison CT; Lin CS; Christensen O; Calvo E
    Lancet Oncol; 2016 Jul; 17(7):883-895. PubMed ID: 27269741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
    Tykodi SS; Gordan LN; Alter RS; Arrowsmith E; Harrison MR; Percent I; Singal R; Van Veldhuizen P; George DJ; Hutson T; Zhang J; Zoco J; Johansen JL; Rezazadeh Kalebasty A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
    J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
    Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
    Kaseb AO; Hasanov E; Cao HST; Xiao L; Vauthey JN; Lee SS; Yavuz BG; Mohamed YI; Qayyum A; Jindal S; Duan F; Basu S; Yadav SS; Nicholas C; Sun JJ; Singh Raghav KP; Rashid A; Carter K; Chun YS; Tzeng CD; Sakamuri D; Xu L; Sun R; Cristini V; Beretta L; Yao JC; Wolff RA; Allison JP; Sharma P
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):208-218. PubMed ID: 35065057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.
    Juloori A; Katipally RR; Lemons JM; Singh AK; Iyer R; Robbins JR; George B; Hall WA; Pitroda SP; Arif F; Fung J; Pillai A; Liao CY; Sharma M; Liauw SL
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):202-213. PubMed ID: 36108891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
    Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
    Harrington KJ; Ferris RL; Gillison M; Tahara M; Argiris A; Fayette J; Schenker M; Bratland Å; Walker JWT; Grell P; Even C; Chung CH; Redman R; Coutte A; Salas S; Grant C; de Azevedo S; Soulières D; Hansen AR; Wei L; Khan TA; Miller-Moslin K; Roberts M; Haddad R
    JAMA Oncol; 2023 Jun; 9(6):779-789. PubMed ID: 37022706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
    Grimm MO; Esteban E; Barthélémy P; Schmidinger M; Busch J; Valderrama BP; Charnley N; Schmitz M; Schumacher U; Leucht K; Foller S; Baretton G; Duran I; de Velasco G; Priou F; Maroto P; Albiges L;
    Lancet Oncol; 2023 Nov; 24(11):1252-1265. PubMed ID: 37844597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).
    Callahan M; Amin A; Kaye FJ; Morse MA; Taylor MH; Peltola KJ; Sharma P; O'Reilly EM; Meadows Shropshire S; O'Brien S; Tschaika M; Le DT
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38316517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.